Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667367 | 0.73 | EPHX2 (0.40) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL12384847 | 0.71 | EPHX2 (0.50) | EPHX1 | |
| SCHEMBL688621 | 0.68 | SMN1; SMN2 (0.37) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL689352 | 0.68 | SMN1; SMN2 (0.37) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL688620 | 0.68 | SMN1; SMN2 (0.37) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL688228 | 0.67 | TSHR (0.36) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL9071835 | 0.65 | NPSR1 (0.48) | MEN1ALDH1A1KMT2AEPHX1 | |
| SCHEMBL12384849 | 0.65 | NPSR1 (0.48) | MEN1ALDH1A1KMT2AEPHX1 | |
| SCHEMBL689399 | 0.65 | TSHR (0.45) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL687588 | 0.64 | ALDH1A1 (0.43) | MEN1ALDH1A1POLBCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | GCK, HK1, GCKR | MEN1 3017/4885ALDH1A1 2374/4885POLB 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.